A Post-Market Observational Multi-Center Study to Evaluate the Effectiveness of Repeated QUTENZA Use in Adults with Painful Diabetic Peripheral Neuropathy of the Feet
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Capsaicin (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors Averitas Pharma
Most Recent Events
- 26 Mar 2025 Protocol was amended to add new primary endpoints.
- 26 Mar 2025 Planned End Date changed from 1 Dec 2025 to 1 Mar 2027.
- 26 Mar 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2026.